As a clinically active inhibitor, poziotinib binds tightly into the sterically hindered drug-binding pocket of YVMA insertion to overcome structural changes and inhibit HER2-mutant NSCLC more potently than afatinib by in vitro evidence (Robichaux et al., 2018). Here, ERBB2 is linked to non-small cell lung carcinoma.